Home / Business and Economy / Summit Therapeutics Soars on $2B AstraZeneca Deal
Summit Therapeutics Soars on $2B AstraZeneca Deal
29 Sep
Summary
- AstraZeneca invests $2 billion to jointly test cancer treatments.
- The companies will test AstraZeneca's sonesitatug vedotin with Summit's ivonescimab.
- The collaboration aims to target certain gastrointestinal cancers.
Summit Therapeutics' stock experienced a substantial 23% rise in premarket trading following the announcement of a significant collaboration with AstraZeneca. The Anglo-Swedish pharmaceutical giant is investing $2 billion to jointly develop novel cancer treatments.
The agreement centers on testing AstraZeneca's experimental drug, sonesitatug vedotin, in combination with Summit's ivonescimab. This therapeutic pairing is slated for trials targeting specific gastrointestinal cancers. Each company will maintain independent development and commercialization rights for their respective molecular contributions.
Summit's ivonescimab targets two key proteins, PD-1 and VEGF, which are crucial for immune evasion and tumor growth. This mechanism, known as VEGF bispecific, aligns AstraZeneca with competitors like Bristol and Merck in this advanced therapeutic area.
Additionally, the companies plan further trials combining ivonescimab with other AstraZeneca cancer medicines. Analysts view the deal as a strategic validation for Summit, providing essential funding and enhancing its market position, while bolstering AstraZeneca's solid tumor pipeline.
